American Health Intel Rules. Money. Medicine. Decoded daily.
Subscribe
The Ledger · Sunday, November 15, 2026

The Ledger

Rules. Money. Medicine. Decoded daily.
2 stories · 3 min read
Reading as

Charles River Laboratories will pay $470 million in cash, plus up to $75 million more if performance targets are met, for the drug-testing laboratory business of Frontage in Exton, Pennsylvania. Charles River, a contract research organization that tests drugs for developers, announced the deal November 9 in a Charles River press release distributed through Business Wire. The target is Frontage’s bioanalysis and DMPK (drug metabolism and pharmacokinetics) work, two sites of about 150,000 square feet with about 340 employees and a CLIA-certified (Clinical Laboratory Improvement Amendments) central lab. The unit made about 40% of Frontage’s 2025 revenue of $256.7 million, or roughly $103 million by our arithmetic. The deal rides on a take-private of the Hong Kong-listed Frontage by its controlling shareholder Hongkong Tigermed and Chairman Song Li, so closing depends on shareholder, regulatory and Cayman Islands court approvals and is expected in the first half of 2027. Who it hits: drug developers that buy trial lab work, and the smaller testing labs now competing against a larger platform. So what: about 15% of Charles River’s bioanalysis revenue is clinical-phase today, while most of Frontage’s came from clinical development, so the buyer is paying to move later into the trial pipeline. Charles River expects the deal to be neutral to non-GAAP earnings per share in 2027 and accretive after. Confidence: High on the terms, which are in the company’s release; this is a drug-development supplier deal, so its effect on care delivery is indirect. This is six days old; we cover it now because we had not reported it.

Three hospital and post-acute operators filed for Chapter 11 bankruptcy protection between November 1 and November 6, and the common thread is government payment pressure. TapestryHealth, a Stratford, Connecticut post-acute care company, filed November 6 in Delaware (case 26-11777) with $10 million to $50 million in liabilities and about $11.7 million in funded secured debt. Bankruptcy-tracker summaries of its first-day filings say the Centers for Medicare & Medicaid Services (CMS) suspended its Medicare payments, Medicare is more than 63% of its revenue, about 50,000 Medicare patients lost service and its workforce fell about 79%. The same summaries say federal prosecutors in the Southern District of New York issued False Claims Act civil investigative demands in April; that is an allegation-stage detail, not a finding. Redeemer Health and affiliates in Pennsylvania filed November 1 (case 26-14631) after missing September and October payments on about $71 million of bonds, and the board says it will sell or close Holy Redeemer Hospital while keeping its senior care units. Roseland Community Hospital in Chicago filed November 4 (case 26-18477) with $10 million to $50 million in liabilities, citing delayed state and Medicaid payments and expected Medicaid cuts. Who it hits: bondholders and lenders to safety-net and post-acute operators, and staffing and supply vendors, which are among Roseland’s largest unsecured creditors. So what: for lenders and vendors, payer-side payment holds and bond covenant misses are the early signals, and they came months before these petitions. Confidence: Med on the filing dates and case numbers; Low to Med on the causes and dollar figures, which come from trackers summarizing court filings, not the dockets. Sources: Bondoro Redeemer Health filing alert, Bondoro TapestryHealth filing alert, WhatNow Roseland report, supplemental trade sources only; the primary court dockets were not reviewed.

A note on today’s scan: it is Sunday, and we found no new transaction announced in the last 24 hours, no earnings filings from the large insurers or hospital operators, and no new rating agency action on a health system. Surgery Partners, whose amended $25 per share HealthSpan Partners deal (announced November 9) and reported $28 rival proposal we covered earlier this week, filed no new developments we could find. A frontier check of ground and air ambulance operators surfaced only older deals, including Grant Avenue Capital’s January purchase of PatientCare EMS Solutions, per LevinPro.

THE DEAL SHEET

No new transactions spotted in the last 24 hours.

Announced earlier this week and still pending, listed for completeness:

TargetAcquirer/InvestorVerticalValueSource
Frontage bioanalysis and DMPK business (Exton, Pennsylvania)Charles River LaboratoriesClinical trial lab servicesAbout $470 million cash plus up to $75 million contingent (announced November 9)Charles River press release
Surgery PartnersHealthSpan Partners (Bon Secours Mercy Health affiliate); Bain Capital rolling its stakeAmbulatory surgery centers$25.00 per share cash, enterprise value up to about $6.0 billion (amended November 9)Surgery Partners 8-K exhibit
Healthcare Stat HomecareDavian HealthcareHome care$13.5 million, $8 million cash and $5.5 million in shares (reported November 11)Home Health Care News
Get tomorrow's edition in your inbox.

Free. One email a day at 6pm your time, or one summary every Friday. Switch or stop anytime.

Where these stories are tracked
Get the next issue Free, daily